Publication Name	World Journal of Psychiatry
Manuscript ID	96136
Country	Türkiye

Received	2024-04-27 18:21
Peer-Review Started	2024-04-28 01:31
To Make the First Decision
Return for Revision	2024-07-28 21:38
Revised	2024-07-30 12:51
Second Decision	2024-08-07 02:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-08-07 05:30
Articles in Press	2024-08-07 05:30
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-08-25 04:16
Typeset the Manuscript	2024-08-30 07:17
Publish the Manuscript Online	2024-09-11 07:02

ISSN	2220-3206 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Genetics & Heredity
Manuscript Type	Editorial
Article Title	Personalized medicine and opioid use disorder
Manuscript Source	Invited Manuscript
All Author List	Dilek Kaya-Akyüzlü
ORCID	Author(s) ORCID Number Dilek Kaya-Akyüzlü http://orcid.org/0000-0002-3305-0587
Funding Agency and Grant Number
Corresponding Author	Dilek Kaya-Akyüzlü, PhD, Associate Professor, Institute of Forensic Sciences, Ankara University, Balkiraz Mah. Mamak Cad. No. 27, Dikimevi, Ankara 06590, Türkiye. akyuzludilek@gmail.com
Key Words	Opioid use disorder; Genetic vulnerability; Treatment failures; Personalized medicine; Pharmacogenetics
Core Tip	Although maintenance treatment with methadone or buprenorphine is effective for treating opioid use disorder, the rate of treatment failure is high among patients, which leads to significant costs to society in terms of healthcare and justice. Thus, it is important to understand the genetic information of patients to increase treatment effectiveness. There has been evidence showing the interaction between genetic variants and the rate of metabolism, the mechanism of action and transport of drugs. Therefore, patient-tailored treatment would be a good approach to facilitate longer periods of abstinence in addicts who are at high risk of treatment failure.
Publish Date	2024-09-11 07:02
Citation	<p>Kaya-Akyüzlü D. Personalized medicine and opioid use disorder. <i>World J Psychiatry</i> 2024; 14(9): 1285-1288</p>
URL	https://www.wjgnet.com/2220-3206/full/v14/i9/1285.htm
DOI	https://dx.doi.org/10.5498/wjp.v14.i9.1285

Full Article (PDF)	WJP-14-1285-with-cover.pdf
Manuscript File	96136_Auto_Edited_011036.docx
Answering Reviewers	96136-answering-reviewers.pdf
Audio Core Tip	96136-audio.m4a
Conflict-of-Interest Disclosure Form	96136-conflict-of-interest-statement.pdf
Copyright License Agreement	96136-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	96136-non-native-speakers.pdf
Peer-review Report	96136-peer-reviews.pdf
Scientific Misconduct Check	96136-scientific-misconduct-check.png
Scientific Editor Work List	96136-scientific-editor-work-list.pdf
CrossCheck Report	96136-crosscheck-report.png
CrossCheck Report	96136-crosscheck-report.pdf